Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.
Total revenues were down due to lower assay revenues, which shrank 11 percent from a year ago. Sample-to-answer molecular product revenues grew 15 percent.
The firm beat Wall Street analyst estimates for revenues and earnings per share in the third quarter.
Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
The firm beat analysts' revenue expectations for the quarter while its net loss was in line with predictions.
The company missed analysts' consensus estimate for revenues but beat Wall Street expectations on the bottom line.
The firm said genomic testing volume rose 23 percent year over year, and raised its revenue guidance for full-year 2018.
The company reported $5.92 billion in revenues for the quarter, driven by growth across its four business segments.
Though the firm's total revenues were down year over year, its product and service revenue soared on sales of its ConfirmMDx Prostate cancer assay.
Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.